Dena Sharp
San Francisco, CA
Girard Sharp LLP
Brown University
University of California College of the Law, San Francisco
Dena Sharp is a problem solver who simplifies even the most complicated issues in class action litigation.
Dena currently represents prescription drug purchasers as co-lead counsel in In re Restasis Antitrust Litigation and as a member of the End-Payer Steering Committee in In re Generic Pharmaceuticals Pricing Antitrust Litigation, a massive price-fixing case against dozens of drug companies. She also represents clients of a fertility center whose eggs and embryos were affected by a freezer tank malfunction.
As co-lead counsel in In re Lidoderm Antitrust Litigation, a “pay-for-delay” antitrust case that settled for $104.75 million on the eve of trial, Dena worked with her team to win class certification, defeat summary judgment, and obtain the largest recovery for a class of end-payers in similar federal litigation in more than a decade. She has also played a key role in a variety of other high-profile cases, including representing investors in litigation arising from Lehman Brothers’ bankruptcy and in matters involving Ponzi schemes and accounting fraud.
Outside the courtroom, Dena is co-author of the widely-cited Sedona Principles: Best Practices and Principles for Electronic Document Production (Third Edition). She serves on the board of directors of the Impact Fund, a public interest nonprofit, and as vice chair of the Advisory Council for the Duke Law School Center for Judicial Studies. An editor of the Duke Law Proportionality Guidelines and Best Practices, Dena is also co-author of a chapter in a forthcoming ABA book on class action practice and strategy.
A first-generation American, Dena is fluent in Spanish and German.
